BTSG BRIGHTSPRING HEALTH SERVICES INC.

BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®

BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya®

LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are experiencing extravascular hemolysis (EVH).

Voydeya® is FDA-approved as add-on therapy to Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients living with PNH that experience continued anemia, or EVH. This innovative drug will complement current treatment regimens and help regulate the immune system, providing control and preventing the destruction of healthy blood cells.

“While PNH is only curable via bone marrow transplantation, this innovative drug from Alexion is a significant advancement in the treatment of PNH with EVH and will help improve the lives of those impacted by this disease,” said BrightSpring’s President and CEO, Jon Rousseau. “We are extremely proud of Onco360® for being selected as the preferred pharmacy for Voydeya® as it shows the company’s commitment to supporting cutting-edge treatment options the best possible way for patients living with cancer and complex diseases. We commend their leadership in partnering with biopharmaceutical leaders to continually innovate the proven standard-of-care.”

“Onco360® is grateful and honored to partner with Alexion Pharmaceuticals to treat and support patients living with PNH with EVH and improve their quality of life,” said Benito Fernandez, Chief Commercial Officer at Onco360®. “This is another highly specialized, first-in-class drug that will complement current treatment regimens, and we’re proud to be a trusted pharmacy and implement leading clinical and service practices for this drug and patients.”

Onco360®operates with the mission to improve the lives of patients battling cancer and living with other challenging and rare diseases. The pharmacy has robust access to limited distribution oncology medications and offers personalized services such as financial assistance sourcing, insurance benefit verification, expert clinical counseling, physician, patient and family education and support, rapid and accurate order processing and drug fulfillment, real-time digital and data support, Hub services, and 24/7 patient support.

To learn more about Onco360® and BrightSpring, please visit .

About BrightSpring Health Services 

BrightSpring Health Services is the parent company of leading service lines that provide complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the company’s service lines, including pharmacy, primary care and home health care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily. 

About Onco360 Oncology Pharmacy

Onco360 is one of the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing over 350,000 patients in healthcare facilities and at home in the United States every day. For more information about Onco360, please visit .

Media Contact:  

Leigh White



502.630.7412



EN
10/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BRIGHTSPRING HEALTH SERVICES INC.

 PRESS RELEASE

BrightSpring Health Services, Inc. Reports First Quarter 2024 Financia...

BrightSpring Health Services, Inc. Reports First Quarter 2024 Financial Results and Increases Full Year 2024 Guidance LOUISVILLE, Ky., May 02, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the first quarter ended March 31, 2024, and increases 2024 revenue and Adjusted EBITDA1 guidance. Financial Highlights Net Revenue of $2,577 million, up 27.0%...

 PRESS RELEASE

BrightSpring Health Services, Inc. Welcomes Timothy A. Wicks to Board ...

BrightSpring Health Services, Inc. Welcomes Timothy A. Wicks to Board of Directors LOUISVILLE, Ky., April 26, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced that on April 24, 2024, BrightSpring appointed Timothy A. Wicks as a new member of the Board of Directors. Mr. Wicks will assume his new role effective immediately, bringing the Company’s total Board of Directors to seven members, including two independent directors. Mr...

 PRESS RELEASE

BrightSpring Health Services Specialty Pharmacy Onco360® Selected as N...

BrightSpring Health Services Specialty Pharmacy Onco360® Selected as National Pharmacy Partner for Voydeya® LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) announced today that its company Onco360®, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH...

 PRESS RELEASE

BrightSpring Health Services, Inc. to Announce First Quarter 2024 Fina...

BrightSpring Health Services, Inc. to Announce First Quarter 2024 Financial Results on May 2, 2024, and Participate in the Bank of America 2024 Healthcare Conference LOUISVILLE, Ky., April 09, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its first quarter 2024 financial results on Thursday, May 2, 2024, prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day. To participate in the conference call, please register before the 8:30 a.m. ET sta...

 PRESS RELEASE

BrightSpring Health Services Applauds Hundreds of Award-Winning Employ...

BrightSpring Health Services Applauds Hundreds of Award-Winning Employees for their Recognition of Outstanding Service and Care LOUISVILLE, Ky., April 04, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or “the Company”) (NASDAQ: BTSG) applauds its most recent employees and programs for their dedicated service, care, and innovation, which has resulted in ongoing and additional national recognition by industry publications and trade associations. Since 2017, over 200 of BrightSpring’s individual employees have now been recognized for their award-winning leade...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch